Ainos (AIMD)

AI Nose uses gas sensor arrays together with proprietary artificial intelligence models to identify chemical signatures associated with odors and airborne compounds. Ainos refers to this AI layer as a smell language model, or SLM. The system is designed to generate a Smell ID, a digital representation of scent data that can be analyzed by software. Potential applications for this type of technology include industrial monitoring, healthcare screening, environmental sensing, food quality control and other areas where the detection of volatile organic compounds can provide useful information.

The company’s second platform is VELDONA, a low-dose oral interferon program. Interferons are naturally occurring proteins involved in immune system signaling, and Ainos is developing therapeutic assets based on this approach. While AI Nose represents the company’s primary strategic focus, the VELDONA program gives Ainos a biotechnology component alongside its artificial intelligence and sensor technology work.

Ainos is distinctive because it combines AI, hardware sensors and life sciences rather than operating as a pure software company or a traditional drug developer. Its prospects depend on the commercialization of digital smell applications, validation of its sensor and AI models, partnerships in target industries, and progress in its therapeutic pipeline. For investors, the company sits at the intersection of emerging machine olfaction, diagnostic technology and immunology.